Print PDF

Sheppard Mullin Advises Underwriters in connection with HCW Biologics' Initial Public Offering


Sheppard Mullin advised the underwriters in connection with a $56 million initial public offering of Common Stock of HCW Biologics, Inc.  HCW Biologics’ shares began trading on the Nasdaq Capital Market on July 20, 2021 under the ticker symbol “HCWB.”  HCW Biologics is an innovative preclinical stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases.

The Sheppard Mullin corporate team included partners Richard Friedman and Stephen Cohen, associate Taylor Ashton and law clerk Brett Uslaner. Partner Jing Liu provided advice on Intellectual Property matters, and Partner Allison Fulton provided advice on FDA Regulatory matters. Members of the Sheppard Mullin team are based in the New York, Del Mar, Los Angeles and Washington, D.C. offices.

Click here to read the press release.

Practice Areas


Jump to Page

By scrolling this page, clicking a link or continuing to browse our website, you consent to our use of cookies as described in our Cookie and Advertising Policy. If you do not wish to accept cookies from our website, or would like to stop cookies being stored on your device in the future, you can find out more and adjust your preferences here.